$ORKA

$95.97 +$0.16 (0.17%) Close

$ORKA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 66.2M shares outstanding

Who owns ORKA?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 109.1%

Harwin Peter Evan 22.0% · Kiselak Tomas 22.0%

Institutional ownership

100.0%

+20.3 pts vs last qtr

Institutional holders

254

+70 vs last qtr

Net shares bought

+21.4M

by institutions in Q2 2026

New / sold out

100 / 30

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Capital World Investors NEW +3.4M
FMR LLC +1.6M

Biggest sellers in Q2 2026

Viking Global Investors LP −1.2M
Mercer Global Advisors Inc /adv SOLD OUT −802.5K

Who is planning to sell?

Notices of proposed sale, last 12 months

$337M

17 notices from 8 people

Shares covered

4.0M

6.12% of the company

Arranged in advance

11%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Fairmount Healthcare Fund II L.P. Director, 10% stockholder $300M
Lawrence Klein Director 10b5-1 $9.03M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2021–FY2023

+3.7%

+1.82% a year

Each share's claim on the business

−3.6%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $1.74M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years62% Under 1 year38%

Quarterly turnover

31.4%

of institutional shares changed hands

Top 10 managers, median time held

1.8 years

Super Investors

Investment managers reporting ORKA on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
F FMR LLC	9.1M	13.68%	+1.6M (+21.9%)	2024	0.0%
Shares held by quarter Peak holding9.1M (Q2'26) Change over 8 quarters+4.4M Share of the company13.680% FMR LLC's full portfolio →
B BlackRock, Inc.	5.0M	7.54%	+1.5M (+41.5%)	2024	0.0%
Shares held by quarter Peak holding5.0M (Q2'26) Change over 8 quarters+5.0M Share of the company7.540% BlackRock, Inc.'s full portfolio →

FMR LLC

9.1M

% of company

13.68%

Change vs last qtr

+1.6M (+21.9%)

Held since

2024

BlackRock, Inc.

5.0M

% of company

7.54%

Change vs last qtr

+1.5M (+41.5%)

Held since

2024

28 more super investors behind a free account

See every manager holding Oruka Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ORKA on Form N-PORT; together they hold 38.5% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$164M	1.7M	2.60%	0.01%	June 30, 2026
SS State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR Series Trust	$148M	1.6M	2.35%	1.38%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$164M

% of company

2.60%

% of the fund

0.01%

As of

June 30, 2026

State Street(R) SPDR(R) S&P(R) Biotech ETF

SPDR Series Trust

Position value

$148M

% of company

2.35%

% of the fund

1.38%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Oruka Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
HP Harwin Peter Evan 5%+ holder 13D · 19.5%	14.6M	22.01%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company22.010% Disclosed stake13D · 19.5% View the 13D/G filing →
KT Kiselak Tomas 5%+ holder 13D · 19.5%	14.5M	21.95%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company21.950% Disclosed stake13D · 19.5% View the 13D/G filing →

Harwin Peter Evan

5%+ holder13D · 19.5%

14.6M

% of company

22.01%

Change vs last qtr

—

Held since

—

Kiselak Tomas

5%+ holder13D · 19.5%

14.5M

% of company

21.95%

Change vs last qtr

—

Held since

—

9 more holders behind a free account

See every insider and 5%+ holder of Oruka Therapeutics, Inc..

Comments